AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15318308 — intervention group
Group type: EXPERIMENTAL
Intervention: ml/kg RBW and ml/kg OBW methods
Number of subjects: 120
Study 15318308 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall RCM&PV measurements
Number of subjects: 120
Study 11315840 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 20
Study 11315840 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 20
Study 11315840 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet treatment
Number of subjects: 20
Study 11315840 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic patients (control group)
Number of subjects: 20
Study 9221965 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (150 mg/day for 31 days)
Number of subjects: 33
Study 9221965 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 33
Study 8501992 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for community pharmacists
Number of subjects: 762
Study 2880663 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg t.i.d.)
Number of subjects: 24
Study 2880663 — intervention group
Group type: EXPERIMENTAL
Intervention: Visacor (200 mg once daily)
Number of subjects: 24
Study 31515083 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab treatment with early tumor shrinkage (ETS) defined as a reduction of ≥ 30% in the sum of the longest diameters of lesions at 8 weeks.
Number of subjects: 659
Study 31515083 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab treatment with depth of response (DpR) calculated as maximum percentage change in tumor size from baseline to nadir.
Number of subjects: 659
Study 31515083 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with symptoms at baseline who experienced ETS ≥ 30%.
Number of subjects: 659
Study 28206871 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly progressive resistance training (PRT) and three times weekly swallowing exercises by physio- and occupational therapists, with daily home exercises throughout radiotherapy.
Number of subjects: 240
Study 28206871 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 240
Study 25985395 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-managed medication therapy management (MTM) program administered at four visits over 6 months
Number of subjects: 101
Study 25985395 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-managed medication therapy management (MTM) program
Number of subjects: 101
Study 25985395 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (no specific intervention mentioned)
Number of subjects: 101
Study 24111980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (40-160 mg/day based on weight)
Number of subjects: 237
Study 24111980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 24111980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (in OLE)
Number of subjects: 237
Study 24111980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (in RCT)
Number of subjects: 237
Study 24111980 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in RCT)
Number of subjects: 237
Study 21346105 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-micronutrient supplementation (daily biscuit)
Number of subjects: 865
Study 19234585 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA) supplementation in flax oil (14 g/day)
Number of subjects: 51
Study 19234585 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (3 days a week)
Number of subjects: 51
Study 19234585 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 51
Study 16492009 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support intervention
Number of subjects: 0
Study 16492009 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12969584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 68
Study 12969584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 10636263 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg for 16 weeks
Number of subjects: 20
Study 10636263 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 20
Study 8615492 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 19
Study 8615492 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine (1/200,000)
Number of subjects: 19
Study 1418771 — intervention group
Group type: COMPARATOR
Intervention: Room air exposure (0.7% carboxyhemoglobin)
Number of subjects: 30
Study 1418771 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower carbon monoxide exposure (3.2% carboxyhemoglobin)
Number of subjects: 30
Study 1418771 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher carbon monoxide exposure (5.1% carboxyhemoglobin)
Number of subjects: 30
Study 6386511 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline 300 mg tablets t.i.d.
Number of subjects: 25
Study 6386511 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 300 mg tablets (Theo-Dur®) t.i.d.
Number of subjects: 25
Study 6386511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 6386511 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 25
Study 6386511 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 25
Study 31405365 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep tissue laser therapy (DTLT)
Number of subjects: 40
Study 31405365 — intervention group
Group type: COMPARATOR
Intervention: Sham laser therapy (SLT)
Number of subjects: 40
Study 30170645 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (SK)
Number of subjects: 52
Study 30170645 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK)
Number of subjects: 52
Study 24490806 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste-masked FXD-ODTs (F23) with camphor (20%, w/w) and a more hydrophilic lubricant (Pruv®)
Number of subjects: 0
Study 24490806 — intervention group
Group type: COMPARATOR
Intervention: Allegra® tablets (phenylalanine-containing ODT)
Number of subjects: 0
Study 23441887 — intervention group
Group type: EXPERIMENTAL
Intervention: Health professional-led Chronic Disease Self-Management Support (CDSMS) programme (the Flinders Program)
Number of subjects: 50
Study 23441887 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 50
Study 23441887 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSMS programme
Number of subjects: 50
Study 23441887 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSMS sessions presence
Number of subjects: 50
Study 23441887 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 50
Study 20496157 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down costing approach
Number of subjects: 156
Study 20496157 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottom-up costing approach
Number of subjects: 156
Study 20496157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 156
Study 20496157 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156
Study 19476231 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cognition Training Program (including emotion recognition training and social perception training)
Number of subjects: 14
Study 19476231 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 14
Study 17203353 — intervention group
Group type: EXPERIMENTAL
Intervention: Serenoa repens (SR) 320 mg per day
Number of subjects: 60
Study 17203353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (TAM) 0.4 mg per day
Number of subjects: 60
Study 17203353 — intervention group
Group type: EXPERIMENTAL
Intervention: Serenoa repens (SR) + Tamsulosin (TAM)
Number of subjects: 60
Study 14667698 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming with functional value of color information
Number of subjects: 5
Study 14667698 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming with functional value of pattern information
Number of subjects: 5
Study 11731389 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire method (parents completing a health questionnaire at age 2 years)
Number of subjects: 472
Study 11731389 — intervention group
Group type: COMPARATOR
Intervention: Routine data collection method (community clerks following children's progress)
Number of subjects: 472
Study 7962890 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral treatment 1
Number of subjects: 2
Study 7962890 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral treatment 2
Number of subjects: 2
Study 7962890 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 2
Study 3116609 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine‐CO2 at 36 degrees C
Number of subjects: 90
Study 3116609 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine‐HCl at 36 degrees C
Number of subjects: 90
Study 29205343 — intervention group
Group type: EXPERIMENTAL
Intervention: Honest, Open, Proud (HOP) program
Number of subjects: 98
Study 29205343 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 98
Study 27059658 — intervention group
Group type: EXPERIMENTAL
Intervention: Benchmarking CT dataset contouring and planning according to trial protocol
Number of subjects: 33
Study 27059658 — intervention group
Group type: EXPERIMENTAL
Intervention: Deviations from trial contouring protocol
Number of subjects: 33
Study 26299563 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-delivered intervention
Number of subjects: 154
Study 23553618 — intervention group
Group type: EXPERIMENTAL
Intervention: High hardaliye (HH) - 500 mL per day
Number of subjects: 89
Study 23553618 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hardaliye (LH) - 250 mL per day
Number of subjects: 89
Study 23553618 — intervention group
Group type: COMPARATOR
Intervention: Control group - no hardaliye
Number of subjects: 89
Study 20537468 — intervention group
Group type: EXPERIMENTAL
Intervention: Early excision and skin grafting (E&G)
Number of subjects: 50
Study 20537468 — intervention group
Group type: COMPARATOR
Intervention: Delayed skin grafting
Number of subjects: 50
Study 18779777 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive risperidone therapy
Number of subjects: 0
Study 18779777 — intervention group
Group type: EXPERIMENTAL
Intervention: PaRTS‐A
Number of subjects: 0
Study 16266782 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level experts
Number of subjects: 0
Study 16266782 — intervention group
Group type: COMPARATOR
Intervention: Low-level players and nonplayers
Number of subjects: 0
Study 12795574 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent problem-solving (PPS) intervention
Number of subjects: 127
Study 12795574 — intervention group
Group type: COMPARATOR
Intervention: Problem-solving skills training (PSST) and parent management training (PMT)
Number of subjects: 127
Study 11201319 — intervention group
Group type: EXPERIMENTAL
Intervention: Insert earphones
Number of subjects: 41
Study 11201319 — intervention group
Group type: COMPARATOR
Intervention: Sound field
Number of subjects: 41
Study 9118743 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorectal manometry
Number of subjects: 152
Study 9118743 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoanal sonography
Number of subjects: 152
Study 8396956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin (KABI 2165)
Number of subjects: 12
Study 8396956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparine (CY 216)
Number of subjects: 12
Study 8396956 — intervention group
Group type: EXPERIMENTAL
Intervention: Clexane (PK 10169)
Number of subjects: 12
Study 8396956 — intervention group
Group type: EXPERIMENTAL
Intervention: Orgaran (Org 10172)
Number of subjects: 12
Study 3080511 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (load), 30 mg once daily for 1 week and then 10 mg once daily for 1 week
Number of subjects: 32
Study 3080511 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 50 mg once daily for 2 weeks
Number of subjects: 32
Study 3080511 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine, 60 mg twice daily for 2 weeks
Number of subjects: 32
Study 3080511 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (no load), 10 mg once daily for 2 weeks
Number of subjects: 32
Study 3080511 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study 31655073 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive counseling staff training intervention
Number of subjects: 756
Study 31655073 — intervention group
Group type: COMPARATOR
Intervention: Usual counseling (Control)
Number of subjects: 756
Study 29611401 — intervention group
Group type: EXPERIMENTAL
Intervention: LDCT‐IR
Number of subjects: 112
Study 29611401 — intervention group
Group type: COMPARATOR
Intervention: SDCT
Number of subjects: 112
Study 26816604 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.9 mg/day
Number of subjects: 360
Study 26816604 — intervention group
Group type: COMPARATOR
Intervention: Additional OAD
Number of subjects: 360
Study 24971591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispositional mindfulness (labeling and describing inner experiences)
Number of subjects: 0
Study 24971591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispositional mindfulness (accepting negative thoughts and feelings without judgment)
Number of subjects: 0
Study 24971591 — intervention group
Group type: COMPARATOR
Intervention: Psychological distress
Number of subjects: 0
Study 24573588 — intervention group
Group type: EXPERIMENTAL
Intervention: Subatmospheric pressure therapy (SPT)
Number of subjects: 178
Study 19952828 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (aerobic exercise training for 4 months)
Number of subjects: 162
Study 19952828 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonexercise)
Number of subjects: 162
Study 18215526 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory oddball task performed simultaneously with driving task
Number of subjects: 20
Study 18215526 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving task performed simultaneously with auditory oddball task
Number of subjects: 20
Study 18215526 — intervention group
Group type: COMPARATOR
Intervention: Driving task and secondary oddball task performed in isolation
Number of subjects: 20
Study 15870519 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopy quality control reviewers examining digitized cervical images
Number of subjects: 0
Study 14501542 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention (n=437)
Number of subjects: 598
Study 10541503 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Helicobacter pylori infection
Number of subjects: 1122
Study 10541503 — intervention group
Group type: COMPARATOR
Intervention: Age and sex matched controls
Number of subjects: 1122
Study 10541503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibling pairs with discordant H pylori status
Number of subjects: 1122
Study 10541503 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted odds ratio after smoking and socioeconomic status
Number of subjects: 1122
Study 10541503 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted odds ratio after blood lipid concentrations and obesity
Number of subjects: 1122
Study 10541503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibling pairs
Number of subjects: 1122
Study 9025711 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 3 IU/m2 per day for 14 days
Number of subjects: 8
Study 9025711 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 6 IU/m2 per day for 14 days
Number of subjects: 8
Study 9025711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1603479 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oxytocin (6-mU/minute dosage increments)
Number of subjects: 2788
Study 4004603 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (20 mg daily or less)
Number of subjects: 16
Study 31025209 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) and fractional ablative CO2 laser (FACL) treatment (three sessions at 1-month intervals)
Number of subjects: 18
Study 31025209 — intervention group
Group type: COMPARATOR
Intervention: Standard moisturizers and silicone gels (control treatment)
Number of subjects: 18
Study 29061568 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 334
Study 29061568 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP plus RT
Number of subjects: 334
Study 27393388 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal counseling
Number of subjects: 170
Study 27393388 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 170
Study 27393388 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 170
Study 24625717 — intervention group
Group type: EXPERIMENTAL
Intervention: Real TMS at 110% of the estimated prefrontal cortex threshold to the left dorsolateral prefrontal cortex, 15 sessions, 325‐second trains of 10‐Hz repetitive TMS, total of 24,000 pulses
Number of subjects: 68
Study 24625717 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS, 15 sessions, 325‐second trains of 10‐Hz repetitive TMS, total of 24,000 pulses
Number of subjects: 68
Study 22612620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (LPZ) intravenous infusion at doses of 15 mg, 30 mg, and 60 mg
Number of subjects: 12
Study 22612620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (LPZ) intravenous infusion
Number of subjects: 12
Study 20299988 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 microg ml(‐1)
Number of subjects: 128
Study 20299988 — intervention group
Group type: COMPARATOR
Intervention: Control group (without clonidine)
Number of subjects: 128
Study 17999638 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C+E (1 g/day vitamin C plus 400 IU/day vitamin E)
Number of subjects: 110
Study 17999638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 16060278 — intervention group
Group type: EXPERIMENTAL
Intervention: Static-dynamic exercise (SDE)
Number of subjects: 75
Study 16060278 — intervention group
Group type: COMPARATOR
Intervention: Standard dynamic exercise (SDE)
Number of subjects: 75
Study 12194626 — intervention group
Group type: EXPERIMENTAL
Intervention: Home rehabilitation with an average of 4.6 physiotherapist visits
Number of subjects: 81
Study 12194626 — intervention group
Group type: COMPARATOR
Intervention: Institutional rehabilitation lasting on average 36.2 days (SD 14.6) with daily physiotherapy
Number of subjects: 81
Study 10091618 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden (5 mg intravenously)
Number of subjects: 17
Study 10091618 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (subcutaneously, previously determined dose)
Number of subjects: 17
Study 8953073 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental rhinovirus infection (cases)
Number of subjects: 11
Study 8953073 — intervention group
Group type: COMPARATOR
Intervention: Noninfected saline‐challenged young adults (controls)
Number of subjects: 11
Study 2026847 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (20 nmol)
Number of subjects: 7
Study 2026847 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 7
Study 2026847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 7
Study 2026847 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (M1 antagonist)
Number of subjects: 7
Study 2026847 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-DAMP (M3 antagonist)
Number of subjects: 7
Study 2026847 — intervention group
Group type: EXPERIMENTAL
Intervention: AFDX-116 (M2 antagonist)
Number of subjects: 7
Study 2026847 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamines (pretreatment)
Number of subjects: 7
Study 6410736 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 40
Study 6410736 — intervention group
Group type: COMPARATOR
Intervention: Renografin‐76 (diatrizoate meglumine and diatrizoate sodium)
Number of subjects: 40
Study 6410736 — intervention group
Group type: EXPERIMENTAL
Intervention: Both iohexol and Renografin‐76
Number of subjects: 40
Study 30092143 — intervention group
Group type: EXPERIMENTAL
Intervention: H56:IC31 vaccine (two or three vaccinations at different concentrations)
Number of subjects: 98
Study 30092143 — intervention group
Group type: EXPERIMENTAL
Intervention: H56:IC31 vaccine (three vaccinations)
Number of subjects: 98
Study 30092143 — intervention group
Group type: EXPERIMENTAL
Intervention: H56:IC31 vaccine (various doses)
Number of subjects: 98
Study 30092143 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied as control)
Number of subjects: 98
Study 30149332 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) + CBT, n = 70
Number of subjects: 142
Study 30149332 — intervention group
Group type: COMPARATOR
Intervention: Placebo + CBT
Number of subjects: 142
Study 30149332 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) + CBT
Number of subjects: 142
Study 27481884 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg of sodium hyaluronate in 3 mL of a 0.9% sodium saline solution
Number of subjects: 116
Study 27481884 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride saline solution
Number of subjects: 116
Study 25301251 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-weighing intervention with a set of weighing scales
Number of subjects: 183
Study 25301251 — intervention group
Group type: COMPARATOR
Intervention: Control group (received two weight loss consultations known to be ineffective)
Number of subjects: 183
Study 22870245 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise training (AET)
Number of subjects: 0
Study 22870245 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 0